Citations (139)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Yanmin Zhang, Mingliang Zhang, Yuchen Wang, Yuanrong Fan, Xingye Chen, Yan Yang, Yi Hua, Wuchen Xie, Tao Lu, Weifang Tang, Yadong Chen & Haichun Liu. (2020) Protein–ligand interaction-guided discovery of novel VEGFR-2 inhibitors. Journal of Biomolecular Structure and Dynamics 38:9, pages 2559-2574.
Read now
Read now
Qingxin Mu, Jesse Yu, Lisa A. McConnachie, John C. Kraft, Yu Gao, Gaurav K. Gulati & Rodney J. Y. Ho. (2018) Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook. Journal of Drug Targeting 26:5-6, pages 435-447.
Read now
Read now
Vivek Kumar Singh, Hsin-Huei Chang, Ching-Chuan Kuo, Hui-Yi Shiao, Hsing-Pang Hsieh & Mohane Selvaraj Coumar. (2017) Drug repurposing for chronic myeloid leukemia: in silico and in vitro investigation of DrugBank database for allosteric Bcr-Abl inhibitors. Journal of Biomolecular Structure and Dynamics 35:8, pages 1833-1848.
Read now
Read now
Bryan Oronsky, Ramasamy Paulmurugan, Kira Foygel, Jan Scicinski, Susan J. Knox, Donna Peehl, Hongjuan Zhao, Shoucheng Ning, Pedro Cabrales, Thomas A. Summers$suffix/text()$suffix/text(), Tony R. Reid, William L. Fitch, Michelle M. Kim, Jane B. Trepel, Min-Jung Lee, Santosh Kesari, Nacer D. Abrouk, Regina M. Day, Arnold Oronsky, Carolyn M. Ray & Corey A. Carterg. (2017) RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials. Expert Opinion on Investigational Drugs 26:1, pages 109-119.
Read now
Read now
Marie-Françoise Heymann, Hannah K. Brown & Dominique Heymann. (2016) Drugs in early clinical development for the treatment of osteosarcoma. Expert Opinion on Investigational Drugs 25:11, pages 1265-1280.
Read now
Read now
Ivan Fraietta & Fabio Gasparri. (2016) The development of high-content screening (HCS) technology and its importance to drug discovery. Expert Opinion on Drug Discovery 11:5, pages 501-514.
Read now
Read now
Claudia Maria Hattinger, Marilù Fanelli, Elisa Tavanti, Serena Vella, Stefano Ferrari, Piero Picci & Massimo Serra. (2015) Advances in emerging drugs for osteosarcoma. Expert Opinion on Emerging Drugs 20:3, pages 495-514.
Read now
Read now
Matteo Morotti, Christian M Becker, Mario Valenzano Menada & Simone Ferrero. (2013) Targeting tyrosine-kinases in ovarian cancer. Expert Opinion on Investigational Drugs 22:10, pages 1265-1279.
Read now
Read now
Paul Bamborough. (2012) System-based drug discovery within the human kinome. Expert Opinion on Drug Discovery 7:11, pages 1053-1070.
Read now
Read now
Vito W Rebecca & Keiran SM Smalley. (2011) Tumor heterogeneity and strategies to overcome kinase inhibitor resistance in cancer: lessons from melanoma. Expert Opinion on Investigational Drugs 20:2, pages 137-140.
Read now
Read now
Articles from other publishers (129)
Yang Yang, Hong Li, Hua Xie & Jiqing Hao. (2023) Carrier-free, pure nanodrugs based on dasatinib and 5-Fluorouracil show aggregation-induced emission and enhanced antitumor efficacy. Journal of Drug Delivery Science and Technology 90, pages 105142.
Crossref
Crossref
Mohammed Y. Behairy, Refaat A. Eid, Hassan M. Otifi, Heitham M. Mohammed, Mohammed A. Alshehri, Ashwag Asiri, Majed Aldehri, Mohamed Samir A. Zaki, Khaled M. Darwish, Sameh S. Elhady, Nahla H. El-Shaer & Muhammad Alaa Eldeen. (2023) Unraveling Extremely Damaging IRAK4 Variants and Their Potential Implications for IRAK4 Inhibitor Efficacy. Journal of Personalized Medicine 13:12, pages 1648.
Crossref
Crossref
Ngo Hoang Long & Sook-Jeong Lee. (2023) Targeting casein kinase 1 for cancer therapy: current strategies and future perspectives. Frontiers in Oncology 13.
Crossref
Crossref
Chen Hu, Lijuan Shen, Fengming Zou, Yun Wu, Beilei Wang, Aoli Wang, Chao Wu, Li Wang, Jing Liu, Wenchao Wang & Qingsong Liu. (2023) Predicting and overcoming resistance to CDK9 inhibitors for cancer therapy. Acta Pharmaceutica Sinica B 13:9, pages 3694-3707.
Crossref
Crossref
Svetlana I. Zhuravleva, Anton D. Zadorozhny, Boris V. Shilov & Alexey A. Lagunin. (2023) Prediction of Amino Acid Substitutions in ABL1 Protein Leading to Tumor Drug Resistance Based on “Structure-Property” Relationship Classification Models. Life 13:9, pages 1807.
Crossref
Crossref
Martiniano Bello & Cindy Bandala. (2023) Evaluating the ability of end-point methods to predict the binding affinity tendency of protein kinase inhibitors. RSC Advances 13:36, pages 25118-25128.
Crossref
Crossref
Macario Martínez-Castillo, Laura Gómez-Romero, Hugo Tovar, Irma Olarte-Carrillo, Anel García-Laguna, Gilberto Barranco-Lampón, Adrián De la Cruz-Rosas, Adolfo Martínez-Tovar, Araceli Hernández-Zavala & Emilio J. Córdova. (2023) Genetic alterations in the BCR-ABL1 fusion gene related to imatinib resistance in chronic myeloid leukemia. Leukemia Research 131, pages 107325.
Crossref
Crossref
Vanessa Nguyen, Ethan Ahler, Katherine A. Sitko, Jason J. Stephany, Dustin J. Maly & Douglas M. Fowler. (2023) Molecular determinants of Hsp90 dependence of Src kinase revealed by deep mutational scanning. Protein Science 32:7.
Crossref
Crossref
Pey Yee Lee, Yeelon Yeoh & Teck Yew Low. (2022) A recent update on small‐molecule kinase inhibitors for targeted cancer therapy and their therapeutic insights from mass spectrometry‐based proteomic analysis. The FEBS Journal 290:11, pages 2845-2864.
Crossref
Crossref
Elena Kalinichenko, Aliaksandr Faryna, Tatyana Bozhok, Anna Golyakovich & Alesya Panibrat. (2023) Novel Phthalic-Based Anticancer Tyrosine Kinase Inhibitors: Design, Synthesis and Biological Activity. Current Issues in Molecular Biology 45:3, pages 1820-1842.
Crossref
Crossref
Angélica Sandoval-Pérez, Beth Apsel Winger & Matthew P. Jacobson. (2022) Assessing the Activation of Tyrosine Kinase KIT through Free Energy Calculations. Journal of Chemical Theory and Computation 18:10, pages 6251-6258.
Crossref
Crossref
Chunlong Zhao & Frank J. Dekker. (2022) Novel Design Strategies to Enhance the Efficiency of Proteolysis Targeting Chimeras. ACS Pharmacology & Translational Science 5:9, pages 710-723.
Crossref
Crossref
Sam Crowl, Ben T. Jordan, Hamza Ahmed, Cynthia X. Ma & Kristen M. Naegle. (2022) KSTAR: An algorithm to predict patient-specific kinase activities from phosphoproteomic data. Nature Communications 13:1.
Crossref
Crossref
Mrinal Shekhar, Zachary Smith, Markus A. Seeliger & Pratyush Tiwary. (2022) Protein Flexibility and Dissociation Pathway Differentiation Can Explain Onset of Resistance Mutations in Kinases**. Angewandte Chemie International Edition 61:28.
Crossref
Crossref
Mrinal Shekhar, Zachary Smith, Markus A. Seeliger & Pratyush Tiwary. (2022) Protein Flexibility and Dissociation Pathway Differentiation Can Explain Onset of Resistance Mutations in Kinases**. Angewandte Chemie 134:28.
Crossref
Crossref
Ekaterina Shevchenko & Tatu Pantsar. (2022) Regulatory spine RS3 residue of protein kinases: a lipophilic bystander or a decisive element in the small-molecule kinase inhibitor binding?. Biochemical Society Transactions 50:1, pages 633-648.
Crossref
Crossref
Jude S. Bimela, Aubin J. Nanfack, Pengpeng Yang, Shaoxing Dai, Xiang-Peng Kong, Judith N. Torimiro & Ralf Duerr. (2022) Antiretroviral Imprints and Genomic Plasticity of HIV-1 pol in Non-clade B: Implications for Treatment. Frontiers in Microbiology 12.
Crossref
Crossref
Alaa Abdelatty, Dan Fang, Guanqun Wei, Fubing Wu, Chengfei Zhang, Haojun Xu, Chengyun Yao, Yundong Wang & Hongping Xia. (2022) PKCι Is a Promising Prognosis Biomarker and Therapeutic Target for Pancreatic Cancer. Pathobiology 89:6, pages 370-381.
Crossref
Crossref
Tao Xie, Tamjeed Saleh, Paolo Rossi, Darcie Miller & Charalampos G. Kalodimos. (2022) Imatinib can act as an Allosteric Activator of Abl Kinase. Journal of Molecular Biology 434:2, pages 167349.
Crossref
Crossref
Chirasmita Nayak & Sanjeev Kumar Singh. 2022. Protein Kinase Inhibitors. Protein Kinase Inhibitors
71
96
.
Suparna Ghosh, Seketoulie Keretsu & Seung Joo Cho. (2021) Molecular Modeling Studies of N-phenylpyrimidine-4-amine Derivatives for Inhibiting FMS-like Tyrosine Kinase-3. International Journal of Molecular Sciences 22:22, pages 12511.
Crossref
Crossref
Baswanth Oruganti & Ran Friedman. (2021) Activation of Abl1 Kinase Explored Using Well-Tempered Metadynamics Simulations on an Essential Dynamics Sampled Path. Journal of Chemical Theory and Computation 17:11, pages 7260-7270.
Crossref
Crossref
Mohammad M. Al-Sanea, Garri Chilingaryan, Narek Abelyan, Arsen Sargsyan, Sargis Hovhannisyan, Hayk Gasparyan, Smbat Gevorgyan, Sarah Albogami, Mohammed M. Ghoneim, Ahmed K. Farag, Ahmed A. B. Mohamed & Ashraf K. El-Damasy. (2021) Identification of Novel Potential VEGFR-2 Inhibitors Using a Combination of Computational Methods for Drug Discovery. Life 11:10, pages 1070.
Crossref
Crossref
Chen Wang, Yukari Okita, Ling Zheng, Yasuhiro Shinkai, Lev Manevich, Jas M. Chin, Tomokazu Kimura, Hiroyuki Suzuki, Yoshito Kumagai & Mitsuyasu Kato. (2021) Glycoprotein non–metastatic melanoma protein B functions with growth factor signaling to induce tumorigenesis through its serine phosphorylation. Cancer Science 112:10, pages 4187-4197.
Crossref
Crossref
Zheng Ren, Qian Li, Yiwen Shen & Ling Meng. (2021) Intrinsic relative preference profile of pan-kinase inhibitor drug staurosporine towards the clinically occurring gatekeeper mutations in Protein Tyrosine Kinases. Computational Biology and Chemistry 94, pages 107562.
Crossref
Crossref
Massimo Serra, Claudia Maria Hattinger, Michela Pasello, Chiara Casotti, Leonardo Fantoni, Chiara Riganti & Maria Cristina Manara. (2021) Impact of ABC Transporters in Osteosarcoma and Ewing’s Sarcoma: Which Are Involved in Chemoresistance and Which Are Not?. Cells 10:9, pages 2461.
Crossref
Crossref
Jian-Bo Tong, Ding Luo, Shuai Bian & Xing Zhang. (2021) Structural investigation of tetrahydropteridin analogues as selective PLK1 inhibitors for treating cancer through combined QSAR techniques, molecular docking, and molecular dynamics simulations. Journal of Molecular Liquids 335, pages 116235.
Crossref
Crossref
Danda Chapagai, Gurusankar Ramamoorthy, Jessy Varghese, Elmar Nurmemmedov, Campbell McInnes & Michael D. Wyatt. (2021) Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells. Journal of Medicinal Chemistry 64:14, pages 9916-9925.
Crossref
Crossref
Natasha P. MurphyHelen R. Mott & Darerca Owen. (2021) Progress in the therapeutic inhibition of Cdc42 signalling. Biochemical Society Transactions 49:3, pages 1443-1456.
Crossref
Crossref
Claudia Maria Hattinger, Maria Pia Patrizio, Leonardo Fantoni, Chiara Casotti, Chiara Riganti & Massimo Serra. (2021) Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies. Cancers 13:12, pages 2878.
Crossref
Crossref
Mafalda Antunes‐Ferreira, Danijela Koppers‐Lalic & Thomas Würdinger. (2020) Circulating platelets as liquid biopsy sources for cancer detection. Molecular Oncology 15:6, pages 1727-1743.
Crossref
Crossref
Pora Kim, Hanyang Li, Junmei Wang & Zhongming Zhao. (2021) Landscape of drug-resistance mutations in kinase regulatory hotspots. Briefings in Bioinformatics 22:3.
Crossref
Crossref
David Kreutzer, Henry Döring, Peter Werner, Christoph A. Ritter & Andreas Hilgeroth. (2021) Novel Symmetrical Cage Compounds as Inhibitors of the Symmetrical MRP4-Efflux Pump for Anticancer Therapy. International Journal of Molecular Sciences 22:10, pages 5098.
Crossref
Crossref
Christian Boni & Claudio Sorio. (2021) Current Views on the Interplay between Tyrosine Kinases and Phosphatases in Chronic Myeloid Leukemia. Cancers 13:10, pages 2311.
Crossref
Crossref
Alessandro Allegra, Chiara Imbesi, Alessandra Bitto & Roberta Ettari. (2021) Drug Repositioning for the Treatment of Hematologic Disease: Limits, Challenges and Future Perspectives. Current Medicinal Chemistry 28:11, pages 2195-2217.
Crossref
Crossref
Richard A. Ward, Stephen Fawell, Nicolas Floc’hVikki FlemingtonDarren McKerrecherPaul D. Smith. (2020) Challenges and Opportunities in Cancer Drug Resistance. Chemical Reviews 121:6, pages 3297-3351.
Crossref
Crossref
Mehmet Erguven, Tülay Karakulak, M. Kasim Diril & Ezgi Karaca. (2021) How Far Are We from the Rapid Prediction of Drug Resistance Arising Due to Kinase Mutations?. ACS Omega 6:2, pages 1254-1265.
Crossref
Crossref
Ruifeng Hu, Haodong Xu, Peilin Jia & Zhongming Zhao. (2021) KinaseMD: kinase mutations and drug response database. Nucleic Acids Research 49:D1, pages D552-D561.
Crossref
Crossref
Xiaona Chen, Zhen Hu, Liqian Zhou, Fu Zhang, Jianqin Wan & Hangxiang Wang. (2021) Self-assembling a natural small molecular inhibitor that shows aggregation-induced emission and potentiates antitumor efficacy. Nanoscale Horizons 6:1, pages 33-42.
Crossref
Crossref
Luca Mologni, Giovanni Marzaro, Sara Redaelli & Alfonso Zambon. (2021) Dual Kinase Targeting in Leukemia. Cancers 13:1, pages 119.
Crossref
Crossref
Yunzhuo Zhou, Stephanie Portelli, Megan Pat, Carlos H.M. Rodrigues, Thanh-Binh Nguyen, Douglas E.V. Pires & David B. Ascher. (2021) Structure-guided machine learning prediction of drug resistance mutations in Abelson 1 kinase. Computational and Structural Biotechnology Journal 19, pages 5381-5391.
Crossref
Crossref
Lokeswari P. Tangella, Michael E. Clark & Elin S. Gray. (2021) Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review. Biochimica et Biophysica Acta (BBA) - General Subjects 1865:1, pages 129736.
Crossref
Crossref
Henry Döring, David Kreutzer, Christoph Ritter & Andreas Hilgeroth. (2020) Discovery of Novel Symmetrical 1,4-Dihydropyridines as Inhibitors of Multidrug-Resistant Protein (MRP4) Efflux Pump for Anticancer Therapy. Molecules 26:1, pages 18.
Crossref
Crossref
Sanjay K. Srikakulam, Tomas Bastys & Olga V. Kalinina. (2020)
A shift of dynamic equilibrium between the
KIT
active and inactive states causes drug resistance
. Proteins: Structure, Function, and Bioinformatics 88:11, pages 1434-1446.
Crossref
Crossref
Qiuhong Liu, Jinqiao Zhou, Jing Gao, Wentao Ma, Shilei Wang & Lihua Xing. (2020) Rational design of EGFR dimerization-disrupting peptides: A new strategy to combat drug resistance in targeted lung cancer therapy. Biochimie 176, pages 128-137.
Crossref
Crossref
Marc Hoemberger, Warintra Pitsawong & Dorothee Kern. (2020) Cumulative mechanism of several major imatinib-resistant mutations in Abl kinase. Proceedings of the National Academy of Sciences 117:32, pages 19221-19227.
Crossref
Crossref
Christos Liolios, Antonio Shegani, Ioanna Roupa, Christos Kiritsis, Ata Makarem, Maria Paravatou-Petsotas, Maria Pelecanou, Penelope Bouziotis, Minas Papadopoulos, Klaus Kopka & Ioannis Pirmettis. (2020) Synthesis, characterization and evaluation of 68Ga labelled monomeric and dimeric quinazoline derivatives of the HBED-CC chelator targeting the epidermal growth factor receptor. Bioorganic Chemistry 100, pages 103855.
Crossref
Crossref
B. Sobottka & A. Weber. (2020) Molekulare Tumordiagnostik – aktuelle Methoden, Anwendungsbeispiele und AusblickMolecular tumor diagnostics—current methods, examples of application and future. Der Pathologe 41:4, pages 411-424.
Crossref
Crossref
Reihane Ziadlou, Andrea Barbero, Ivan Martin, Xinluan Wang, Ling Qin, Mauro Alini & Sibylle Grad. (2020) Anti-Inflammatory and Chondroprotective Effects of Vanillic Acid and Epimedin C in Human Osteoarthritic Chondrocytes. Biomolecules 10:6, pages 932.
Crossref
Crossref
Jacob J. Adashek, Shumei Kato, Rahul Parulkar, Christopher W. Szeto, J. Zachary Sanborn, Charles J. Vaske, Stephen C. Benz, Sandeep K. Reddy & Razelle Kurzrock. (2020) Transcriptomic silencing as a potential mechanism of treatment resistance. JCI Insight 5:11.
Crossref
Crossref
Zheng Zhao & Philip E. Bourne. (2020) Revealing Acquired Resistance Mechanisms of Kinase-Targeted Drugs Using an on-the-Fly, Function-Site Interaction Fingerprint Approach. Journal of Chemical Theory and Computation 16:5, pages 3152-3161.
Crossref
Crossref
Ning-Yu Wang, Ying Xu, Kun-Jie Xiao, Wei-Qiong Zuo, Yong-Xia Zhu, Rong Hu, Wan-Li Wang, Yao-Jie Shi, Luo-Ting Yu & Zhi-Hao Liu. (2020) Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors. European Journal of Medicinal Chemistry 191, pages 112152.
Crossref
Crossref
B. Sobottka & A. Weber. (2020) Molekulare Tumordiagnostik – aktuelle Methoden, Anwendungsbeispiele und AusblickMolecular tumor diagnostics—current methods, examples of application and future. Der Onkologe 26:4, pages 373-386.
Crossref
Crossref
Taciani de Almeida Magalhães, Graziella Ribeiro de Sousa, Gustavo Alencastro Veiga Cruzeiro, Luiz Gonzaga Tone, Elvis Terci Valera & Kleiton Silva Borges. (2020) The therapeutic potential of Aurora kinases targeting in glioblastoma: from preclinical research to translational oncology. Journal of Molecular Medicine 98:4, pages 495-512.
Crossref
Crossref
Tamara B. Garcia, Rizvan C. Uluisik, Annemie A. van Linden, Kenneth L. Jones, Sujatha Venkataraman, Rajeev Vibhakar & Christopher C. Porter. (2020) Increased HDAC Activity and c-MYC Expression Mediate Acquired Resistance to WEE1 Inhibition in Acute Leukemia. Frontiers in Oncology 10.
Crossref
Crossref
Mauro Angiolini. 2020. Structural Biology in Drug Discovery. Structural Biology in Drug Discovery
363
393
.
Catherine Zilberg, Matthew Weicai Lee, Spiridoula Kraitsek, Bruce Ashford, Marie Ranson, Kerwin Shannon, N Gopalakrishna Iyer, Sydney Ch’ng, Tsu-Hui (Hubert) Low, Carsten Palme, Jonathan Clark, Ruta Gupta & Bing Yu. (2020) Is high-risk cutaneous squamous cell carcinoma of the head and neck a suitable candidate for current targeted therapies?. Journal of Clinical Pathology 73:1, pages 17-22.
Crossref
Crossref
Soma Ghosh, Ilaria Marrocco & Yosef Yarden. 2020. Receptor Tyrosine Kinases. Receptor Tyrosine Kinases
1
57
.
Eman M.E. Dokla, Chun-Sheng Fang, Khaled A.M. Abouzid & Ching S. Chen. (2019) 1,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC. European Journal of Medicinal Chemistry 182, pages 111607.
Crossref
Crossref
Concepción Sánchez-Martínez, María José Lallena, Sonia Gutiérrez Sanfeliciano & Alfonso de Dios. (2019) Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015–2019). Bioorganic & Medicinal Chemistry Letters 29:20, pages 126637.
Crossref
Crossref
Sean T. Toenjes, Valeria Garcia, Sean M. Maddox, Gregory A. Dawson, Maria A. Ortiz, F. Javier Piedrafita & Jeffrey L. Gustafson. (2019) Leveraging Atropisomerism to Obtain a Selective Inhibitor of RET Kinase with Secondary Activities toward EGFR Mutants. ACS Chemical Biology 14:9, pages 1930-1939.
Crossref
Crossref
Bin Li, Ho Lam Chan & Pingping Chen. (2019) Immune Checkpoint Inhibitors: Basics and Challenges. Current Medicinal Chemistry 26:17, pages 3009-3025.
Crossref
Crossref
Dongwook Kim, Yixing Sun, Dan Xie, Kyle E. Denton, Hao Chen, Hang Lin, Michael K. Wendt, Carol Beth Post & Casey J. Krusemark. (2019) Application of a Substrate-Mediated Selection with c-Src Tyrosine Kinase to a DNA-Encoded Chemical Library. Molecules 24:15, pages 2764.
Crossref
Crossref
Srinivasaraghavan Kannan, Stephen J. Fox & Chandra S. Verma. (2019)
Exploring Gatekeeper Mutations in
EGFR
through Computer Simulations
. Journal of Chemical Information and Modeling 59:6, pages 2850-2858.
Crossref
Crossref
Bhaskar Venkata Kameswara Subrahmanya Lakkakula, Batoul Farran, Saikrishna Lakkakula, Sujatha Peela, Nagendra Sastry Yarla, Pallaval Veera Bramhachari, Mohammad Amjad Kamal, Madhu Sudhana Saddala & Ganji Purnachandra Nagaraju. (2019) Small molecule tyrosine kinase inhibitors and pancreatic cancer—Trials and troubles. Seminars in Cancer Biology 56, pages 149-167.
Crossref
Crossref
Pranitha Jenardhanan, Manivel Panneerselvam & Premendu P. Mathur. (2019) Targeting Kinase Interaction Networks: A New Paradigm in PPI Based Design of Kinase Inhibitors. Current Topics in Medicinal Chemistry 19:6, pages 467-485.
Crossref
Crossref
Panagiota S. Georgoulia, Guido Todde, Sinisa Bjelic & Ran Friedman. (2019) The catalytic activity of Abl1 single and compound mutations: Implications for the mechanism of drug resistance mutations in chronic myeloid leukaemia. Biochimica et Biophysica Acta (BBA) - General Subjects 1863:4, pages 732-741.
Crossref
Crossref
Molly R. Ryan, Christal D. Sohl, BeiBei Luo & Karen S. Anderson. (2019) The FGFR1 V561M Gatekeeper Mutation Drives AZD4547 Resistance through STAT3 Activation and EMT. Molecular Cancer Research 17:2, pages 532-543.
Crossref
Crossref
Tingting Meng, Guoxi Qiu, Yun Hong, Ming Yuan, Binbin Lu, Jie Wu, Hong Yuan & Fuqiang Hu. (2019) Effect of chitosan based glycolipid-like nanocarrier in prevention of developing acquired drug resistance in tri-cycle treatment of breast cancer. International Journal of Pharmaceutics 555, pages 303-313.
Crossref
Crossref
Marissa L. Cann, Laura E. Herring, Lauren L. Haar, Thomas S. K. Gilbert, Dennis Goldfarb, Kristy L. Richards, Lee M. Graves & David S. Lawrence. (2018) Dasatinib Is Preferentially Active in the Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma. Journal of Proteome Research.
Crossref
Crossref
Aeri Lee, Seungpyo Hong & Dongsup Kim. (2018) KRDS: a web server for evaluating drug resistance mutations in kinases by molecular docking. Journal of Cheminformatics 10:1.
Crossref
Crossref
Teresa Kaserer & Julian Blagg. (2018) Combining Mutational Signatures, Clonal Fitness, and Drug Affinity to Define Drug-Specific Resistance Mutations in Cancer. Cell Chemical Biology 25:11, pages 1359-1371.e2.
Crossref
Crossref
Cory A. Ocasio, Alexander A. Warkentin, Patrick J. McIntyreKrister J. Barkovich, Clare VeselyJohn Spencer, Kevan M. Shokat & Richard Bayliss. (2018) Type II Kinase Inhibitors Targeting Cys-Gatekeeper Kinases Display Orthogonality with Wild Type and Ala/Gly-Gatekeeper Kinases. ACS Chemical Biology 13:10, pages 2956-2965.
Crossref
Crossref
Robert S. McNeill, Emily E. Stroobant, Erin Smithberger, Demitra A. Canoutas, Madison K. Butler, Abigail K. Shelton, Shrey D. Patel, Juanita C. Limas, Kasey R. Skinner, Ryan E. Bash, Ralf S. Schmid & C. Ryan Miller. (2018) PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition. PLOS ONE 13:7, pages e0200014.
Crossref
Crossref
Kevin Hauser, Christopher Negron, Steven K. Albanese, Soumya Ray, Thomas Steinbrecher, Robert Abel, John D. Chodera & Lingle Wang. (2018) Predicting resistance of clinical Abl mutations to targeted kinase inhibitors using alchemical free-energy calculations. Communications Biology 1:1.
Crossref
Crossref
Andreas Wicki, Nicholas Brown, Alexandros Xyrafas, Vincent Bize, Hanne Hawle, Simona Berardi, Nataša Cmiljanović, Vladimir Cmiljanović, Michael Stumm, Saša Dimitrijević, Richard Herrmann, Vincent Prêtre, Reto Ritschard, Alexandar Tzankov, Viviane Hess, Alexa Childs, Cinta Hierro, Jordi Rodon, Dagmar Hess, Markus Joerger, Roger von Moos, Cristiana Sessa & Rebecca Kristeleit. (2018) First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13). European Journal of Cancer 96, pages 6-16.
Crossref
Crossref
Fleur M. Ferguson & Nathanael S. Gray. (2018) Kinase inhibitors: the road ahead. Nature Reviews Drug Discovery 17:5, pages 353-377.
Crossref
Crossref
Judith E. Unterlass, Arnaud Baslé, Timothy J. Blackburn, Julie Tucker, Céline Cano, Martin E.M. Noble & Nicola J. Curtin. (2016) Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer. Oncotarget 9:17, pages 13139-13153.
Crossref
Crossref
Yanmin Zhang, Yadong Chen, Danfeng Zhang, Lu Wang, Tao Lu & Yu Jiao. (2017) Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines. Journal of Medicinal Chemistry 61:1, pages 140-157.
Crossref
Crossref
Qingliang Shen, Veer S. Bhatt, Inna Krieger, James C. Sacchettini & Jae-Hyun Cho. (2018) Structure-guided design of a potent peptide inhibitor targeting the interaction between CRK and ABL kinase. MedChemComm 9:3, pages 519-524.
Crossref
Crossref
Mahalakshmi Ramadoss & Vijayalakshmi Mahadevan. (2018) Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors. Drug Discovery Today 23:1, pages 76-89.
Crossref
Crossref
Hai-Tsang Huang, Dennis Dobrovolsky, Joshiawa Paulk, Guang Yang, Ellen L. Weisberg, Zainab M. Doctor, Dennis L. Buckley, Joong-Heui Cho, Eunhwa Ko, Jaebong Jang, Kun Shi, Hwan Geun Choi, James D. Griffin, Ying Li, Steven P. Treon, Eric S. Fischer, James E. Bradner, Li Tan & Nathanael S. Gray. (2018) A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader. Cell Chemical Biology 25:1, pages 88-99.e6.
Crossref
Crossref
Steven A. Rosenzweig. 2018.
71
98
.
L. V. K. S. Bhaskar & L. Saikrishna. 2018. Role of Tyrosine Kinases in Gastrointestinal Malignancies. Role of Tyrosine Kinases in Gastrointestinal Malignancies
191
224
.
Helena Kaitsiotou, Marina Keul, Julia Hardick, Thomas Mühlenberg, Julia Ketzer, Christiane Ehrt, Jasmin Krüll, Federico Medda, Oliver Koch, Fabrizio Giordanetto, Sebastian Bauer & Daniel Rauh. (2017) Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT. Journal of Medicinal Chemistry 60:21, pages 8801-8815.
Crossref
Crossref
Tamjeed Saleh, Paolo Rossi & Charalampos G Kalodimos. (2017) Atomic view of the energy landscape in the allosteric regulation of Abl kinase. Nature Structural & Molecular Biology 24:11, pages 893-901.
Crossref
Crossref
Yoshitaka Hiruma, Andre Koch, Nazila Hazraty, Foteini Tsakou, René H. Medema, Robbie P. Joosten & Anastassis Perrakis. (2017) Understanding inhibitor resistance in Mps1 kinase through novel biophysical assays and structures. Journal of Biological Chemistry 292:35, pages 14496-14504.
Crossref
Crossref
Farzin Sohraby, Milad Bagheri, Masoud Aliyar & Hassan Aryapour. (2017) In silico drug repurposing of FDA-approved drugs to predict new inhibitors for drug resistant T315I mutant and wild-type BCR-ABL1: A virtual screening and molecular dynamics study. Journal of Molecular Graphics and Modelling 74, pages 234-240.
Crossref
Crossref
Lee SchwartzbergEdward S. KimDavid LiuDeborah Schrag. (2017) Precision Oncology: Who, How, What, When, and When Not?. American Society of Clinical Oncology Educational Book:37, pages 160-169.
Crossref
Crossref
C. H. C. Halsey, D. H. Thamm, K. M. Weishaar, J. H. Burton, J. B. Charles, D. L. Gustafson, A. C. Avery & E. J. Ehrhart. (2017) Expression of Phosphorylated KIT in Canine Mast Cell Tumor. Veterinary Pathology 54:3, pages 387-394.
Crossref
Crossref
Francisco Martínez-Jiménez, John P. Overington, Bissan Al-Lazikani & Marc A. Marti-Renom. (2017) Rational design of non-resistant targeted cancer therapies. Scientific Reports 7:1.
Crossref
Crossref
Zheng Zhao, Qingsong Liu, Spencer Bliven, Lei Xie & Philip E. Bourne. (2017) Determining Cysteines Available for Covalent Inhibition Across the Human Kinome. Journal of Medicinal Chemistry 60:7, pages 2879-2889.
Crossref
Crossref
Sailu Sarvagalla & Mohane Selvaraj Coumar. 2017. Pharmaceutical Sciences. Pharmaceutical Sciences
1115
1143
.
Suruchi Aggarwal, Manu Kandpal, Shailendra Asthana & Amit Kumar Yadav. 2017. Drug Resistance in Bacteria, Fungi, Malaria, and Cancer. Drug Resistance in Bacteria, Fungi, Malaria, and Cancer
483
510
.
Peter J. Barnes. (2016) Kinases as Novel Therapeutic Targets in Asthma and Chronic Obstructive Pulmonary Disease. Pharmacological Reviews 68:3, pages 788-815.
Crossref
Crossref
A Koch, A Maia, A Janssen & R H Medema. (2015) Molecular basis underlying resistance to Mps1/TTK inhibitors. Oncogene 35:19, pages 2518-2528.
Crossref
Crossref
F Fanini & M Fabbri. (2016) MicroRNAs and cancer resistance: A new molecular plot. Clinical Pharmacology & Therapeutics 99:5, pages 485-493.
Crossref
Crossref
Eric S. Okerberg, Anna Hainley, Heidi Brown, Arwin Aban, Senait Alemayehu, Ann Shih, Jane Wu, Matthew P. Patricelli, John W. Kozarich, Tyzoon Nomanbhoy & Jonathan S. Rosenblum. (2016) Identification of a Tumor Specific, Active-Site Mutation in Casein Kinase 1α by Chemical Proteomics. PLOS ONE 11:3, pages e0152934.
Crossref
Crossref
Marcian E. Van Dort, Hao Hong, Hanxiao Wang, Charles A. Nino, Rachel L. Lombardi, Avery E. Blanks, Stefanie Galbán & Brian D. Ross. (2016) Discovery of Bifunctional Oncogenic Target Inhibitors against Allosteric Mitogen-Activated Protein Kinase (MEK1) and Phosphatidylinositol 3-Kinase (PI3K). Journal of Medicinal Chemistry 59:6, pages 2512-2522.
Crossref
Crossref
Stuart T. Onions, Kazuhiro Ito, Catherine E. Charron, Richard J. Brown, Marie Colucci, Fritz Frickel, George Hardy, Kevin Joly, John King-Underwood, Yasuo Kizawa, Ian Knowles, P. John Murray, Andrew Novak, Anjna Rani, Garth Rapeport, Alun Smith, Peter Strong, David M. Taddei & Jonathan G. Williams. (2016) Discovery of Narrow Spectrum Kinase Inhibitors: New Therapeutic Agents for the Treatment of COPD and Steroid-Resistant Asthma. Journal of Medicinal Chemistry 59:5, pages 1727-1746.
Crossref
Crossref
Jennifer M. Fox, James R. Moynihan, Bryan T. Mott, Jennifer R. Mazzone, Nicole M. Anders, Patrick A. Brown, Michelle A. Rudek, Jun O. Liu, Ravit Arav-Boger, Gary H. Posner, Curt I. Civin & Xiaochun Chen. (2016)
Artemisinin-derived dimer ART-838 potently inhibited human acute leukemias, persisted
in vivo
, and synergized with antileukemic drugs
. Oncotarget 7:6, pages 7268-7279.
Crossref
Crossref
Arnaud Céol, Lisette G. G. C. Verhoef, Mark Wade & Heiko Muller. (2016) Genome and network visualization facilitates the analyses of the effects of drugs and mutations on protein-protein and drug-protein networks. BMC Bioinformatics 17:S4.
Crossref
Crossref
Sailu Sarvagalla & Mohane Selvaraj Coumar. 2016. Applied Case Studies and Solutions in Molecular Docking-Based Drug Design. Applied Case Studies and Solutions in Molecular Docking-Based Drug Design
249
277
.
Romeo Romagnoli, Pier Giovanni Baraldi, Filippo Prencipe, Carlota Lopez-Cara, Riccardo Rondanin, Daniele Simoni, Ernest Hamel, Stefania Grimaudo, Rosaria Maria Pipitone, Maria Meli & Manlio Tolomeo. (2016) Novel iodoacetamido benzoheterocyclic derivatives with potent antileukemic activity are inhibitors of STAT5 phosphorylation. European Journal of Medicinal Chemistry 108, pages 39-52.
Crossref
Crossref
Vadim Bernard-Gauthier, Justin Bailey, Sheldon Berke & Ralf Schirrmacher. (2015) Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET Imaging. Molecules 20:12, pages 22000-22027.
Crossref
Crossref
Silvia Lovera, Maria Morando, Encarna Pucheta-Martinez, Jorge L. Martinez-Torrecuadrada, Giorgio Saladino & Francesco L. Gervasio. (2015) Towards a Molecular Understanding of the Link between Imatinib Resistance and Kinase Conformational Dynamics. PLOS Computational Biology 11:11, pages e1004578.
Crossref
Crossref
A Aubry, S Galiacy, L Ceccato, C Marchand, C Tricoire, F Lopez, R Bremner, C Racaud-Sultan, B Monsarrat, F Malecaze & M Allouche. (2015) Peptides derived from the dependence receptor ALK are proapoptotic for ALK-positive tumors. Cell Death & Disease 6:5, pages e1736-e1736.
Crossref
Crossref
Marcian E. Van Dort, Stefanie Galbán, Hanxiao Wang, Judith Sebolt-Leopold, Christopher Whitehead, Hao Hong, Alnawaz Rehemtulla & Brian D. Ross. (2015) Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor. Bioorganic & Medicinal Chemistry 23:7, pages 1386-1394.
Crossref
Crossref
Abbarna A. Cumaraswamy, Andrew M. Lewis, Mulu Geletu, Aleksandra Todic, Diego B. Diaz, Xin Ran Cheng, Carla E. Brown, Rob C. Laister, David Muench, Kagan Kerman, H. Leighton Grimes, Mark D. Minden & Patrick T. Gunning. (2014) Nanomolar-Potency Small Molecule Inhibitor of STAT5 Protein. ACS Medicinal Chemistry Letters 5:11, pages 1202-1206.
Crossref
Crossref
J. Jean Cui. (2014) A New Challenging and Promising Era of Tyrosine Kinase Inhibitors. ACS Medicinal Chemistry Letters 5:4, pages 272-274.
Crossref
Crossref
Yusuke Narita, Kiyoshi Okamoto, Megumi Ikemori Kawada, Kazuma Takase, Yukinori Minoshima, Kotaro Kodama, Masao Iwata, Norimasa Miyamoto & Kohei Sawada. (2014) Novel ATP-Competitive MEK Inhibitor E6201 Is Effective against Vemurafenib-Resistant Melanoma Harboring the MEK1-C121S Mutation in a Preclinical Model. Molecular Cancer Therapeutics 13:4, pages 823-832.
Crossref
Crossref
Pablo Carbonell & Jean-Yves Trosset. (2014) Overcoming drug resistance through in silico prediction. Drug Discovery Today: Technologies 11, pages 101-107.
Crossref
Crossref
Fiona P. Bailey, Veselin I. Andreev & Patrick A. Eyers. 2014. Protein Kinase Inhibitors in Research and Medicine. Protein Kinase Inhibitors in Research and Medicine
117
146
.
E Tavanti, V Sero, S Vella, M Fanelli, F Michelacci, L Landuzzi, G Magagnoli, R Versteeg, P Picci, C M Hattinger & M Serra. (2013) Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma. British Journal of Cancer 109:10, pages 2607-2618.
Crossref
Crossref
Carles Corbi-Verge, Fabrizio Marinelli, Ana Zafra-Ruano, Javier Ruiz-Sanz, Irene Luque & José D. Faraldo-Gómez. (2013) Two-state dynamics of the SH3–SH2 tandem of Abl kinase and the allosteric role of the N-cap. Proceedings of the National Academy of Sciences 110:36.
Crossref
Crossref
Andliena Tahiri, Kathrine Røe, Anne H. Ree, Rik de Wijn, Karianne Risberg, Christian Busch, Per E. Lønning, Vessela Kristensen & Jürgen Geisler. (2013) Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant Melanoma. PLoS ONE 8:8, pages e72692.
Crossref
Crossref
Sui Huang & Stuart Kauffman. (2013) How to escape the cancer attractor: Rationale and limitations of multi-target drugs. Seminars in Cancer Biology 23:4, pages 270-278.
Crossref
Crossref
Shun Zhu, Sue M. Travis & Adrian H. Elcock. (2013) Accurate Calculation of Mutational Effects on the Thermodynamics of Inhibitor Binding to p38α MAP Kinase: A Combined Computational and Experimental Study. Journal of Chemical Theory and Computation 9:7, pages 3151-3164.
Crossref
Crossref
Daniel Martinez MolinaRozbeh JafariMarina IgnatushchenkoTakahiro SekiE. Andreas LarssonChen DanLekshmy SreekumarYihai CaoPär Nordlund. (2013) Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay. Science 341:6141, pages 84-87.
Crossref
Crossref
Matthew J. Cooper, Nathan J. Cox, Eric I. Zimmerman, Brian J. Dewar, James S. Duncan, Martin C. Whittle, Thien A. Nguyen, Lauren S. Jones, Sreerupa Ghose Roy, David M. Smalley, Pei Fen Kuan, Kristy L. Richards, Richard I. Christopherson, Jian Jin, Stephen V. Frye, Gary L. Johnson, Albert S. Baldwin & Lee M. Graves. (2013) Application of Multiplexed Kinase Inhibitor Beads to Study Kinome Adaptations in Drug-Resistant Leukemia. PLoS ONE 8:6, pages e66755.
Crossref
Crossref
Serge Y. Fuchs. (2013) Hope and Fear for Interferon: The Receptor-Centric Outlook on the Future of Interferon Therapy. Journal of Interferon & Cytokine Research 33:4, pages 211-225.
Crossref
Crossref
Lee M. GravesJames S. DuncanMartin C. WhittleGary L. Johnson. (2013) The dynamic nature of the kinome. Biochemical Journal 450:1, pages 1-8.
Crossref
Crossref
Hong-Ye Zhao, Hongjiang Wei & Xin Wang. (2013) The Reciprocal Interaction of Small Molecule Protein Kinase Inhibitors and ATP-Binding Cassette Transporters in Targeted Cancer Therapy. Journal of Cancer Research Updates 2:1.
Crossref
Crossref
Takayuki Nakagawa, Shinji Takeuchi, Tadaaki Yamada, Shigeki Nanjo, Daisuke Ishikawa, Takako Sano, Kenji Kita, Takahiro Nakamura, Kunio Matsumoto, Kenichi Suda, Tetsuya Mitsudomi, Yoshitaka Sekido, Toshimitsu Uenaka & Seiji Yano. (2012)
Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in
EGFR
-Mutant Lung Cancer
. Molecular Cancer Therapeutics 11:10, pages 2149-2157.
Crossref
Crossref
Katelin N. Townsend, Luke R. K. Hughson, Katrin Schlie, Vincent I. Poon, Ashley Westerback & Julian J. Lum. (2012) Autophagy inhibition in cancer therapy: metabolic considerations for antitumor immunity. Immunological Reviews 249:1, pages 176-194.
Crossref
Crossref
Xianming Deng, Wenjun Zhou, Ellen Weisberg, Jinhua Wang, Jianming Zhang, Takaaki Sasaki, Erik Nelson, James D. Griffin, Pasi A. Jänne & Nathanael S. Gray. (2012) An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFRα and kit. Bioorganic & Medicinal Chemistry Letters 22:14, pages 4579-4584.
Crossref
Crossref
Luke Whitesell & Nancy U. Lin. (2012) HSP90 as a platform for the assembly of more effective cancer chemotherapy. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1823:3, pages 756-766.
Crossref
Crossref
Qing-Hua Liu, Jing Zhang, Chen-Yan Zhao, Dang-Hui Yu, Hai-Ji Bu, Ying Chen, Can-Yong Ni & Ming-Hua Zhu. (2012) Surviving cells after treatment with gemcitabine or 5-fluorouracil for the study of de novo resistance of pancreatic cancer. Cancer Letters 314:1, pages 119-125.
Crossref
Crossref
Carlos García-echeverría. 2011. Kinase Drug Discovery. Kinase Drug Discovery
286
302
.